Pediatric pharmacotherapy. (2020)

• Record Type: Book
• Further Information: Note: Wieland Kiess, Matthias Schwab, Johannes van den Anker, editors.
• Other Names: Kiess, W (Wieland); Schwab, M (Matthias); Anker, Johannes van den
• Contents: Intro -- Preface -- Contents -- Antiepileptic Drugs in Pediatrics -- 1 Evolution of Anti-seizure Medication Development -- 2 ``First-Generation ́́and ``Second-Generation ́́Antiepileptic Drugs -- 2.1 Phenobarbital -- 2.2 Phenytoin -- 2.3 Ethosuximide -- 2.4 Valproate -- 2.5 Vigabatrin -- 2.6 Zonisamide -- 2.7 Lamotrigine -- 2.8 Felbamate -- 2.9 Topiramate -- 2.10 Oxcarbazepine -- 2.11 Levetiracetam -- 3 Newest-Generation (``Third-Generation)́́ Medications -- 3.1 Pregabalin -- 3.2 Lacosamide -- 3.3 Stiripentol -- 3.4 Rufinamide -- 3.5 Eslicarbazepine Acetate -- 3.6 Perampanel 3.7 Brivaracetam -- 3.8 Cannabidiol/Epidiolex -- 3.9 Everolimus -- 4 Drugs in Development -- 4.1 Benzodiazepine Formulations -- 4.2 Bumetanide (NKCC Inhibitor) -- 4.3 Fenfluramine (Amphetamine Derivative) -- 4.4 Ganaxolone (GABAergic) -- 4.5 Huperzine -- 4.6 Ion Channel Modulators -- 4.7 Metabolic Modulators -- References -- Pharmacotherapy of Duchenne Muscular Dystrophy -- 1 Introduction -- 2 Treatment Goals in DMD: Current Landscape -- 3 Treatment Goals in DMD: Pharmacotherapies in the Pipeline -- 4 Treatment Goals in Becker Muscular Dystrophy and Female DMD Carriers -- 5 Looking Forward 3.1.1 What Doses and Intervals Are Needed to Restore Normal Enzyme Activity in Relevant Tissues by Intrathecal Injection? -- 3.1.2 Does the Restored Enzyme Activity Reduce Storage Material and Brain Pathology? -- 3.1.3 Do the Drugs Induce Immune Reaction and/or Other Relevant Adverse Reactions? -- 3.1.4 Does Intrathecal ERT Improve the CNS Disease in MPS? -- 3.2 Trojan Horse Approach with Fusion Proteins -- 3.3 Nanotechnology -- 3.4 Gene Therapy -- 3.5 Cell Microencapsulation -- 3.6 Stop Codon Read-Through -- 3.7 Pharmacological Chaperones -- 3.8 GAG-Reducing Small Molecules -- References Current and Emerging Therapies for Mitochondriopathies -- 1 Introduction -- 2 Current Therapies -- 2.1 Improving Electron Transfer Chain (ETC) Function -- 2.2 Energy Buffer -- 2.3 Antioxidants -- 2.4 Restoration of Nitric Oxide Production -- 3 Emerging Therapies -- 3.1 Stimulation of Mitochondrial Biogenesis -- 3.2 Cardiolipin Protection -- 4 Gene Therapy -- References -- GH and IGF-1 Replacement in Children -- 1 Introduction -- 2 Pathophysiology of GHD -- 3 Treatment of GH-Deficient Children with rhGH -- 4 Treatment of Non-GH-Deficient Children with rhGH
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2020
• Extent: 1 online resource
• Subjects: 615.1083; Pediatric pharmacology; Children -- Diseases -- Chemotherapy; Children -- Diseases -- Chemotherapy; Pediatric pharmacology; Electronic books; Electronic books
• Languages: English
• ISBNs: 9783030504946; 3030504948
• Related ISBNs: 303050493X; 9783030504939
• Notes: Note: References -- Current and Emerging Therapies for Mucopolysaccharidoses -- 1 Introduction -- 2 Current Therapies -- 2.1 Pharmaceutical Characteristics of ERT Medicines -- 2.2 Pharmacology of ERT Medicines -- 2.3 Effects and Limitations of ERT and BMT/HSCT -- 2.3.1 Immunoreactivity -- 2.3.2 Low Bioavailability in Certain Tissues -- 2.3.3 Short-Term Exposure -- 2.3.4 Late Initiation of Treatment -- 3 Emerging Therapies -- 3.1 Intrathecal Enzyme Replacement in MPS I, MPS II, MPS IIIA, and MPS IIIB
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.